Bioavailability of nanomaterials: bridging the gap between nanostructures and their bioactivity.

Instead of the nanostructure and biological activity, this perspective highlights the metabolic processes from biotransformation to bioavailability, to bridge the gap between the cradle (structure design) and endpoint (efficacy and/or safety) of nanomedicines.